'Intelligent medicine' erases side effects

Scientists at Aarhus University, Denmark in collaboration with the biotech company Cytoguide now publish a key to use glucocorticoid steroids in a kind of intelligent medicine that specifically hits the relevant cells. Data are based on rodent studies but if this principle is translated to humans it may greatly improve todays hazardous treatment with this type of potent steroids.

This is the main perspective in the research now published in the recognized research journal Molecular Therapy in the .

Synthetic glucocorticoid steroid are used in many acute and including many such as . This is the most potent anti-inflammatory medicine, but its use is hampered by serious side effects such as osteoporosis, loss in muscle mass, diabetes and immunosuppression.

The new data from the scientists now show that they can target the drugs directly to he 'macrophage' . These cells play a main role in inflammation and their damaging effect on the surrounding tissues is strongly dampened by the glucocorticoid steroids.

The new technology is based on the coupling of the steroids to an antibody that specifically binds to a receptor exclusively expressed on the surface of macrophages. The receptors normally take up haemoglobin but they are also able to engulf drug-conjugates binding to the receptors. In the cells, the active steroid is released and it can now execute it effect (gene regulation).

In this way the drug only works in the relevant cells and much less is needed to obtain full efficacy.

'Our project may initially have relevance for inflammation disease and our focus is now on the that affects many persons with fatty liver due to obesity or alcohol abuses' Soren K. Moestrup from Aarhus University says.

'But this technology may also be applied on completely different types of diseases such as cancer' he continues.

If the scientists get financing and collaboration with the large pharma industry in place they expect to have the first conjugate medicine on the market in about 6 years.

More information: "Targeting the hemoglobin scavenger receptor CD163 in macrophages highly increases the anti-inflammatory potency of dexamethasone". Molecular Therapy.

Related Stories

Designing safer glucocorticoid drugs

date Dec 01, 2010

Glucocorticoid drugs are used widely to treat numerous conditions, including rheumatoid arthritis, allergic reactions, asthma, and some forms of cancer, and transplant recipients.

Recommended for you

Study identifies Ebola virus's Achilles' heel

date 16 hours ago

An international team including scientists from Albert Einstein College of Medicine of Yeshiva University and the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) has identified the ...

Stem cell therapy for inherited skin blistering

date 18 hours ago

Promising results from a trial of a new stem-cell based therapy for a rare and debilitating skin condition have been published in the Journal of Investigative Dermatology. The therapy, involving infusions of ste ...

Simple recipe to make sensory hair cells in the ear

date 18 hours ago

Scientists at the Molecular Medicine Institute in Lisbon, Portugal, and at the University College London Ear Institute, United Kingdom, have developed a simple and efficient protocol to generate inner ear hair cells, the ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.